Successful treatment of dry eye in two patients with chronic graft-versus-host disease with systemic administration of FK506 and corticosteroids

Yoko Ogawa, Shinichiro Okamoto, Masataka Kuwana, Takehiko Mori, Reiko Watanabe, Takeshi Nakajima, Masakazu Yamada, Yukihiko Mashima, Kazuo Tsubota, Yoshihisa Oguchi

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

Purpose. We present two cases of severe dry eye in patients with chronic graft-versus-host disease (CGVHD) after hematopoietic stem cell transplantation (SCT) who were successfully treated by the systemic administration of FK506 and corticosteroids. Methods and Results. A 29-year-old man with chronic myelogenous leukemia underwent SCT. Oral and lung CGVHD developed on approximately day 130, and dry eye associated with CGVHD was diagnosed on day 168. The patient began receiving cyclosporin A (150 mg/d) for the treatment of oral and lung CGVHD. Treatment with prednisolone (1 mg/kg/d) began on approximately day 300. Oral and lung GVHD improved slightly, but worsened again although systemic administration of cyclosporin A and prednisolone were continued. Cyclosporin A was discontinued, and systemic administration of FK506 was started on day 376. Forty-four days later, marked improvement in the ocular surface and other organs was observed. However, the dry eye worsened while tapering FK506, with no flare of other affected organs. A 43-year-old woman with myelodysplastic syndrome underwent SCT. She received FK506 for prophylaxis of CGVHD. She had mild dry eye before SCT. Oral and intestinal CGVHD developed, and the dry eye worsened significantly on approximately day 150 while tapering FK506. Treatment with prednisolone (1 mg/kg/d) began, and the dose of FK506 was increased. By day 240, the symptoms of dry eye and the findings of the ocular surface markedly improved, and CGVHD in other organs was completely resolved. However, the improvement in the dry eye was lost when FK506 was tapered for the second time. Conclusion. Systemic administration of FK506 with corticosteroids is an effective treatment of severe dry eye in patients with CGVHD, but long-term administration may be required to achieve a lasting response. These cases also suggest that further investigation into the use of topical FK506 and prednisolone as a maintenance therapy should be pursued.

Original languageEnglish
Pages (from-to)430-434
Number of pages5
JournalCornea
Volume20
Issue number4
DOIs
Publication statusPublished - 2001

Fingerprint

Tacrolimus
Graft vs Host Disease
Adrenal Cortex Hormones
Prednisolone
Stem Cell Transplantation
Cyclosporine
Therapeutics
Lung
Hematopoietic Stem Cell Transplantation
Myelodysplastic Syndromes
Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Keywords

  • Chronic graft-versus-host disease
  • Corticosteroids
  • Dry eye
  • FK506

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Successful treatment of dry eye in two patients with chronic graft-versus-host disease with systemic administration of FK506 and corticosteroids. / Ogawa, Yoko; Okamoto, Shinichiro; Kuwana, Masataka; Mori, Takehiko; Watanabe, Reiko; Nakajima, Takeshi; Yamada, Masakazu; Mashima, Yukihiko; Tsubota, Kazuo; Oguchi, Yoshihisa.

In: Cornea, Vol. 20, No. 4, 2001, p. 430-434.

Research output: Contribution to journalArticle

Ogawa, Yoko ; Okamoto, Shinichiro ; Kuwana, Masataka ; Mori, Takehiko ; Watanabe, Reiko ; Nakajima, Takeshi ; Yamada, Masakazu ; Mashima, Yukihiko ; Tsubota, Kazuo ; Oguchi, Yoshihisa. / Successful treatment of dry eye in two patients with chronic graft-versus-host disease with systemic administration of FK506 and corticosteroids. In: Cornea. 2001 ; Vol. 20, No. 4. pp. 430-434.
@article{cb29ed7731c84adfbb8196c8fde4d7cb,
title = "Successful treatment of dry eye in two patients with chronic graft-versus-host disease with systemic administration of FK506 and corticosteroids",
abstract = "Purpose. We present two cases of severe dry eye in patients with chronic graft-versus-host disease (CGVHD) after hematopoietic stem cell transplantation (SCT) who were successfully treated by the systemic administration of FK506 and corticosteroids. Methods and Results. A 29-year-old man with chronic myelogenous leukemia underwent SCT. Oral and lung CGVHD developed on approximately day 130, and dry eye associated with CGVHD was diagnosed on day 168. The patient began receiving cyclosporin A (150 mg/d) for the treatment of oral and lung CGVHD. Treatment with prednisolone (1 mg/kg/d) began on approximately day 300. Oral and lung GVHD improved slightly, but worsened again although systemic administration of cyclosporin A and prednisolone were continued. Cyclosporin A was discontinued, and systemic administration of FK506 was started on day 376. Forty-four days later, marked improvement in the ocular surface and other organs was observed. However, the dry eye worsened while tapering FK506, with no flare of other affected organs. A 43-year-old woman with myelodysplastic syndrome underwent SCT. She received FK506 for prophylaxis of CGVHD. She had mild dry eye before SCT. Oral and intestinal CGVHD developed, and the dry eye worsened significantly on approximately day 150 while tapering FK506. Treatment with prednisolone (1 mg/kg/d) began, and the dose of FK506 was increased. By day 240, the symptoms of dry eye and the findings of the ocular surface markedly improved, and CGVHD in other organs was completely resolved. However, the improvement in the dry eye was lost when FK506 was tapered for the second time. Conclusion. Systemic administration of FK506 with corticosteroids is an effective treatment of severe dry eye in patients with CGVHD, but long-term administration may be required to achieve a lasting response. These cases also suggest that further investigation into the use of topical FK506 and prednisolone as a maintenance therapy should be pursued.",
keywords = "Chronic graft-versus-host disease, Corticosteroids, Dry eye, FK506",
author = "Yoko Ogawa and Shinichiro Okamoto and Masataka Kuwana and Takehiko Mori and Reiko Watanabe and Takeshi Nakajima and Masakazu Yamada and Yukihiko Mashima and Kazuo Tsubota and Yoshihisa Oguchi",
year = "2001",
doi = "10.1097/00003226-200105000-00020",
language = "English",
volume = "20",
pages = "430--434",
journal = "Cornea",
issn = "0277-3740",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Successful treatment of dry eye in two patients with chronic graft-versus-host disease with systemic administration of FK506 and corticosteroids

AU - Ogawa, Yoko

AU - Okamoto, Shinichiro

AU - Kuwana, Masataka

AU - Mori, Takehiko

AU - Watanabe, Reiko

AU - Nakajima, Takeshi

AU - Yamada, Masakazu

AU - Mashima, Yukihiko

AU - Tsubota, Kazuo

AU - Oguchi, Yoshihisa

PY - 2001

Y1 - 2001

N2 - Purpose. We present two cases of severe dry eye in patients with chronic graft-versus-host disease (CGVHD) after hematopoietic stem cell transplantation (SCT) who were successfully treated by the systemic administration of FK506 and corticosteroids. Methods and Results. A 29-year-old man with chronic myelogenous leukemia underwent SCT. Oral and lung CGVHD developed on approximately day 130, and dry eye associated with CGVHD was diagnosed on day 168. The patient began receiving cyclosporin A (150 mg/d) for the treatment of oral and lung CGVHD. Treatment with prednisolone (1 mg/kg/d) began on approximately day 300. Oral and lung GVHD improved slightly, but worsened again although systemic administration of cyclosporin A and prednisolone were continued. Cyclosporin A was discontinued, and systemic administration of FK506 was started on day 376. Forty-four days later, marked improvement in the ocular surface and other organs was observed. However, the dry eye worsened while tapering FK506, with no flare of other affected organs. A 43-year-old woman with myelodysplastic syndrome underwent SCT. She received FK506 for prophylaxis of CGVHD. She had mild dry eye before SCT. Oral and intestinal CGVHD developed, and the dry eye worsened significantly on approximately day 150 while tapering FK506. Treatment with prednisolone (1 mg/kg/d) began, and the dose of FK506 was increased. By day 240, the symptoms of dry eye and the findings of the ocular surface markedly improved, and CGVHD in other organs was completely resolved. However, the improvement in the dry eye was lost when FK506 was tapered for the second time. Conclusion. Systemic administration of FK506 with corticosteroids is an effective treatment of severe dry eye in patients with CGVHD, but long-term administration may be required to achieve a lasting response. These cases also suggest that further investigation into the use of topical FK506 and prednisolone as a maintenance therapy should be pursued.

AB - Purpose. We present two cases of severe dry eye in patients with chronic graft-versus-host disease (CGVHD) after hematopoietic stem cell transplantation (SCT) who were successfully treated by the systemic administration of FK506 and corticosteroids. Methods and Results. A 29-year-old man with chronic myelogenous leukemia underwent SCT. Oral and lung CGVHD developed on approximately day 130, and dry eye associated with CGVHD was diagnosed on day 168. The patient began receiving cyclosporin A (150 mg/d) for the treatment of oral and lung CGVHD. Treatment with prednisolone (1 mg/kg/d) began on approximately day 300. Oral and lung GVHD improved slightly, but worsened again although systemic administration of cyclosporin A and prednisolone were continued. Cyclosporin A was discontinued, and systemic administration of FK506 was started on day 376. Forty-four days later, marked improvement in the ocular surface and other organs was observed. However, the dry eye worsened while tapering FK506, with no flare of other affected organs. A 43-year-old woman with myelodysplastic syndrome underwent SCT. She received FK506 for prophylaxis of CGVHD. She had mild dry eye before SCT. Oral and intestinal CGVHD developed, and the dry eye worsened significantly on approximately day 150 while tapering FK506. Treatment with prednisolone (1 mg/kg/d) began, and the dose of FK506 was increased. By day 240, the symptoms of dry eye and the findings of the ocular surface markedly improved, and CGVHD in other organs was completely resolved. However, the improvement in the dry eye was lost when FK506 was tapered for the second time. Conclusion. Systemic administration of FK506 with corticosteroids is an effective treatment of severe dry eye in patients with CGVHD, but long-term administration may be required to achieve a lasting response. These cases also suggest that further investigation into the use of topical FK506 and prednisolone as a maintenance therapy should be pursued.

KW - Chronic graft-versus-host disease

KW - Corticosteroids

KW - Dry eye

KW - FK506

UR - http://www.scopus.com/inward/record.url?scp=0035027771&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035027771&partnerID=8YFLogxK

U2 - 10.1097/00003226-200105000-00020

DO - 10.1097/00003226-200105000-00020

M3 - Article

C2 - 11333336

AN - SCOPUS:0035027771

VL - 20

SP - 430

EP - 434

JO - Cornea

JF - Cornea

SN - 0277-3740

IS - 4

ER -